biogen raised its outlook for profits and revenue on tuesday as investors await full results of the alzheimer’s drug lecanemab   japanbased pharmaceutical firm eisai ticker esaly and biogen biib last month said the phase 3 trial of lecanemab showed a slowdown in the rate of cognitive decline while full results will be made available late next month investors who were prepared for the trial to fail are now waiting to see if the data will satisfy the food and drug administration in the interim biogen reported its thirdquarter adjusted profits of 477 per share more than the 413 per share analysts tracked by factset expected revenue of 25 billion generated in the three months that ended in september matched expectations